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ALTHOUGH there are many biological studies dealing with zinc, little quantiative
data have appeared regarding the concentration and turnover of this metal,
especially for man. Interest in zinc metabolism has been stimulated- by the
accumulating evidence which indicates that this metal is a constituent of several
enzymes (Fischer, Tikkala and Mawson, 1955; Vallee, 1955) and is associated,
also, with some pathological states (Daniel et al., 1956; Prout, Sierp and Whit-
more, 1959; Herring et al., 1961; Fredricks, Tanaka and Valentine, 1960). Our
concern with the element stems from reports of the high concentration of zinc
found in the prostate gland both in animals (Gunn et al., 1955) and man (Mawson
and Fischer, 1952).
While its biological significance is established, the physiological role of zinc
remains to be elucidated. Important contributions to our understanding of
the part played by the element should result from investigations which employ
65Zn. Precise data are not yet available as to the fraction of the administered
radioisotope which is taken up by the various organs. Quantitative concentration
data are unavailable for the prostate; moreover, the particular sites and structures
of the gland associated with 65Zn uptake have not been identified.
Following our earlier study ofthe distribution of65Zn in blood and its excretion
in man (Graig and Siegel, 1960), the present investigation was undertaken to
learn more about the concentration of the radioisotope by several organs with
special attention to the prostate. For the latter, it was also sought to ascertain
which glandular components are implicated in the accumulation of 65Zn.
MATERIALS AND METHODS
Autopsy studies. Fourteen pre-terminal patients having various malignancies
were given approximately 100 ,uc 65Zn (specific activity greater than 75 mc/g.)
as the chloride. The radioisotope was administered as an intravenous infusion
in a 250 ml. volume of isotonic solution. At autopsy, which occurred between
1 and 174 days after the infusion, portions of the following organs were obtained,
whenever possible, for digestion and the assay of 65Zn: liver, pancreas, spleen,
prostate, seminal vesicles, lung, bladder and skeletal muscle.
Studies on prostatic surgical specimens. Tracer doses of 65Zn (approximately
50 ,uc) were administered in the manner described above to 36 patients presumed
to have diseased prostates and awaiting surgery. A sample of each surgical648 E. SIEGEL, F. A. GRAIG, M. M. CRYSTAL AND ELSIE P. SIEGEL
specimen was assayed subsequently for 65Zn concentration, using the technique
outlined below. The variaton of radiozinc localization within the prostate
itselfwas investigated in 15 ofthese patients havingbenignhypertrophy. Multiple
samples were taken from the different lobes (left, right, medial, anterior and
posterior) of the gland for determination of 65Zn.
Digestion of organs.--Duplicate weighed samples of each specimen were
covered and digested with 20 per cent NaOH in a chemical hood employing
moderate heat for several hours. Throughout this period, the level of liquid was
maintained by the addition of distilled water. To determine 65Zn concentration
(per cent dose/g.), aliquots were taken from the resulting suspension for assav.
Recovery experiments were performed on freshly killed mouse organs to
check the reliability of this digestion technique. Known activities of 65Zn
(6-3/uc contained in 1 ml.) were added to duplicate samples ofeach ofthe following
animal organs: brain, lung, spleen, heart, liver, pancreas, kidney, adrenal,
muscle and skin. As indicated in Table I, the results justified employing this
method for the processing of the various human samples.
TABLE I.-Results of 65Zn Recovery Experiments, Following NaOH
Digestion of Various Mouse Organs with Added 65Zn
Per cent
Organ zsZn recovered
Adrenal . 99-5
Brain . 104- 3
Heart . . 100-5
Kidney 101*5
Liver . . 99-5
Lung . . 100.0
Muscle . 100-0
Pancreas . . 99.5
Spleen . 100-5
Skin . 99.5
100- 5 i 16*
* Standard deviation.
Assay Of 65Zn.-Counting of organ suspensions was performed with a well-
type scintillation counter, having a 111 inch diameter Nal-thallium activated
crystal. This detector has a sensitivity of 2-92 x 105 cpm/,ac for 65Zn, established
by calibration against National Bureau of Standards reference solutions. Correc-
tions for physical decay of 65Zn (half-life 244.4 days) were made either from long
term decay curves or from concurrent measurements of aliquots of dose solutions.
Adequate counts were collected to assure an accuracy of better than 5 per cent.
IN vivo counting of prostate.-The localization of 65Zn by the intact prostate
was attempted by using shielded rectal detectors possessing high gamma sensi-
tivity. An Antol type 302 Geiger counter was inserted into a 4 mm. thick lead
housing, whose external diameter was 17-5 mm. With a 1 cm. port at the distal
end, this counting arrangement had a sensitivity of 100 cpm/,uc of 65Zn in contact
with a source whose volume was 1 ml. More recently, a Nuclear-Chicago DS-8
scintillation probe was used similarly; its sensitivity with a 6 mm. diameter
needle probe was 6700 cpm/,ac in contact.DISTRIBUTION OF 65Zn IN MAN
Radioautography
(a) Prostatic sections. To study the localization of the administered radio-
isotope, radioautographs were prepared from 5-10 micron sections of prostate
specimens obtained either at surgery or at autopsy. The organ samples were
fixed overnight in absolute methyl alcohol to minimize loss of 65Zn and then
cleared in xylene. Unstained sections were coated with Kodak Ltd. AR-10
stripping film (Pelc, 1956), exposed for periods ranging between 14 and 250 days
at 4°C. in the presence of a desiccant, after which they were developed for 8
minutes in D-19 developer at 18°C. Following fixing and washing, the radio-
autographs were stained either with hematoxylin and eosin or with methyl
green-pyronin. To check for artifacts, control radioautographs were prepared
from non-radioactive prostatic sections.
(b) Bone marrow smears. About a week after the infusion of 65Zn tracer
doses, bone marrow aspirates from ten patients having no known hematological
disorders were smeared in the darkroom on Kodak NTB plates and fixed with
absolute methyl alcohol (Boyd, 1955). Following exposure for over 200 days
and photographic processing, the plates were stained with Giemsa.
RESULTS
Distribution of 65Zn in various organs and tissues
Widely diff-erent concentrations ofradiozinc were found in the organs obtained
at autopsy (Table II). The highest levels are those of the liver, reaching about
0 050 per cent dose/g. (wet weight) within a few days following administration of
the tagged metal. These values for the concentration in the liver are about
2-8 times greater than those in the pancreas, the next most active organ, and as
much as 10-30 times the levels in muscle, the tissue with the lowest concentration
in our study. Turnover of 65Zn in the liver is apparently slow; as late as 81
days following infusion of the radioisotope, the concentration is still about 0-013
per cent dose/g. The radioisotope is handled more rapidly by the pancreas, so
that the maximum concentration, about 0X023 per cent dose/g., is attained by
the second day. Within a week, the 65Zn level of the pancreas is reduced by
two-thirds, and by 81 days, hardly a tenth remains. The maximum 65Zn
concentration in the spleen, about half that of the pancreas, occurred on the third
day. The small amounts of radiozinc in the seminal vesicles, bladder and muscle
do not appear to change significantly with time.
The radioautographs prepared from the bone marrow smears (Fig. 1-6)
indicate that the greatest amounts of 65Zn are taken up by all early forms of the
hematopoietic series. Megakaryocytes are aiso very heavily labeled. Mature
leucocytes take up lesser amounts of the radioisotope. Since virtually no grains
appear over the erythrocytes, they must contain comparatively little 65Zn. No
difference between the accumulation of radiozinc in nucleus and cytoplasm of
the leucocyte can be discerned.
65Zn concentration by the prostate
Among the organs assayed at autopsy, the prostate holds intermediate rank
with respect to its ability to concentrate 65Zn (Table II). For the eight males
so studied, the mean 65Zn concentration is 0 00495 per cent dose/g. (wet weight)
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with values ranging between 0-00150 and 0 0117. Compared to the other organs,
the ability of the gland to take up administered 65Zn is very variable; it is also
not related to time.
This finding of widely scattered radiozine values independent of the interval
following the infusion of the tracer is reinforced by the measurements made on
the surgical specimens of the prostate obtained from 36 patients (Table III).
For all 44 male patients, the concentrations ranged between 0-00150 and 0-0315
EXPLANATION OF PLATES
FiC. 1-5.-Patient M. K-. Radioautograph of bone marrow smear, prepared 8 davs
following administration of 100 ,uc 65Zn, 215-day exposure. Giemsa.
FIG. 1. Note large number of grains over early forms, fewer over leucocvtes and virtual
absence of grains over erythrocytes. x 180.
FIG. 2.-Megakaryocyte demonstrating marked 65Zn localization. x 405.
FIG. 3. Normoblast showing very high concentration of 66Zn. x 405.
FIG. 4. Myelocyte indicating considerable uptake of radiozinc. x 405.
FIG. 5.-Note moderate 6"Zn uptake in the 4 neutrophils. x 405.
Fie.. 6. Patient F. S-. Radioautograph of bone marrow smear prepared 6 days following
administration of 50 ,uc w6Zn. The metamyelocyte is heavily labeled with 65Zn. 205-day
exposure. Giemsa. x 405.
FIG.- 7.-Patient M. F- (benign prostatic hyperplasia). Radioautograph of prostatic section
from surgical specimen obtained 7 days after administration of 50 ,tc 6"Zn. Distribution
of the radioisotope is spotty and largely confined to the border epithelial cells of the smaller
ancini. 61-day exposure. Methyl green-pyronin. x 42.
Fie. 8. Patient L. E (benign prostatic hyperplasia). Radioautograph of prostatic sectioni
from surgical specimen obtained 21 days after administration of 50 ,uc 65Zn. Parts of
several small acini are labeled with radiozine. 119-day exposure. Methyl green-pyronin.
x42.
FIG. 9.-M. F (same as Fig. 7-different section). Maximum 65Zn localization is along the
luminal border. The prostatic concretions are not as heavily labeled. 136-day exposure.
Methyl green-pyronin. x42.
FIG. 10.- Patient L. E- (same as Fig. 8). One of three adjacent follicles is veiy actively
concentrating the radioisotope. The surrounding stroma does not pick up 6"Zn appre-
ciably. Photographic grains appear principally over the border epithelium. x 180.
FIG. 11. Patient C. L- (benign prostatic hyperplasia). Radioautograph of prostatic section
from surgical specimen obtained 49 days after administration of 50 ptc 6"Zn. Uptake by the
follicle is not uniformi. 65-day exposure. H. and E. x 180.
FiG. 12.-Patient L. E (same as Fig. 8 different section). Variable distribution of 65Zn
in border epithelium of acinus. Methyl green-pyronin. x 405.
FIG. 13. Patient L. E (same as Fig. 8). Microscope focused on photographic grains over
luminal border. x 405.
FIG. 14. Patient L. E -. Sarne field and magnification as Fig. 13, focused on photographic
grains over lumen.
FiCe. 15. Patient C. L (same as Fig. 11). Sequestered cellular material in the holocrine
type acinus is labeled as well as the border epithelial cells of this and the neighboring follicle.
x 180.
FIC. 16.- Patient M. F (same as Fig. 7). 6-5Zn is taken up predominantly by the cytoplasm
of the border epithelial cells. Relatively few grains appear over the adjacent stroma.
x 405.
Fie;. 17.-Patient M. F (same as Fig. 7). Another field demonstrating the localization of
",Zn in the cytoplasm of the acinar epithelium. Lesser amounts of tagged material are
found in the lumen. x 405.
FIG. 18. Patient E. Mc (lymphomna in prostate). Radioautograph of prostatic section
from necropsy specimen obtained 9 days after administration of 50 Iuc 6"Zn. Left: focus
is on grains; right: focus is en the plane ofthe cells. Note that the radioisotope is generally
outside the nucleus. 47-day exposure. Methyl green-pyronin. x 405.BRITISH JOURNAL OF CANCER.
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TABLE 111.-65Zn Concentration (per cent dose/g. wet weight x 10-3)
in the Prostates of 44 Patients
Time from dose 65Zn
Patienit Age (days) concentration
A. Normal Prostate
R.S 32 3 4-46
J. N . . 72 6 10-2
F. S . 60 7 . 3-13
G.S- . 49 81 . 5-60
Average 5-85 ±2 66*.
B. Benign Prostatic Hypetrlasia
B.R 83 . 1 10-3
S. F 76 . 1 5-21
G. C- . . 70 . 2 3-26
J.G 75 3 . 21-2
V. O'G 64 3 6-23
L.H 71 4 8-23
M.P 72 5 . 14 9
B.B 58 5 14-7
G. P 66 5 9-87
W.G 65 15.1
J.C 72 6 22-9
H. S 82 6 5 82
4.F 75 7 17 1
B. C 76 . 7 859
G.M 75 7 9-37
J.D 72 8 689
J.S 82 8 . 6 50
E.A 58 9 . 2 77
M.G 74 9 13-9
S. G . 53 11 187
F.K 75 11 12 3
J.Sc 73 1I . 6-05
X.K . 84 13 10.1
J. St 70 14 19 7
M.G- 77 . 18 4 96
I. Le 68 19 17-1
H.F 73 . 20 10.9
L.E- . 72 21 10 3
M.C . 85 21 12-9
M.T 71 23 31-5
A.W . 76 26 . 10-4
C. L 74 49 . 5-60
J.Mc 56 60 11-7
F. L . 58 174 1-50
I. L 72 . 196 . 4-12
Average 10-78 ± 6.41*.
C. Prostatic Malignatney
J.C 63 . 3 2 44
A. P . 82 4 13-7
H.A . 62 . 8 6-89
L. B . 85 8 . 6-50
E. M- . 52 . 8 6-30
Average 7-17 ± 3.63*
* Standard deviationiDISTRIBUTION OF 65Zn IN MAN
per cent dose/g. during the 196 day period involved. This 20-fold variation in
65Zn concentration among glands was the impetus for investigating the distribution
of the radioisotope within the prostate.
Determinations were made of the 65Zn concentrations in different portions
of the prostate obtained from each of 15 patients undergoing surgery for benign
prostatic hypertrophy (Table IV). The fluctuation in 65Zn values is very great, as
much as a seven-fold range being observed for one case. For 12 of these patients,
the coefficient of variation for the concentration within the gland was greater
than 20 per cent. Moreover, levels of the radioisotope cannot be related con-
sistently to specific anatomical regions of the gland.
TABLE IV.- Variation in 65Zn Concentration (per cent dose/g. wet weight x 10-3)
Within the Hyperplastic Prostate of 15 Patients
Patient A
S. F-
J. G-
L. H-
M. P-
G. P-
Time
from Lobe
dose (number of
Lge (days) samples)
76 1 Right (1)
Left (1)
Median (1)
Anterior (1)
75 . 3 Right (8)
71
72
66
4
5
5
Not identified(6)
Right (4)
Left (8)
B. B- . 58 5 . Right (3)
Left (2)
Median (2)
J. N- . 72 . 6 . Right (1)
Left (1)
Median (1)
Anterior (1)
H. S- 82 . 6 . Right (2)
Left (2)
Posterior (2)
J. D- . 72 . 8 . Right (1)
Left (1)
F. K- 75 . 11 . Right (1)
Left (1)
Anterior (1)
Posterior (1)
J. Sc . 71 . 11 . Not identified
(4)
J. St- . 70 . 14 . Right (2)
Left (2)
M. C- 85 . 21 . Right (8)
M. T- . 71
I. L- . 72
* 23 . Not identified .
(3)
* 196 . Right (1)
Left (1)
Median (1)
Concentration
5-04
5-27
4-65
5-89
11-7, 14-3, 14-3,
16-0, 18-8, 22-1,
35 3, 37-4
6-96, 7 45, 7 73,
8-34, 9-00, 9-85
9-32, 15-1, 17-1,
18-2
6-20, 6-40, 7 37,
8-67, 10-7, 11-2,
12-9, 15-5
4-38, 10-4, 30-0,
14-9, 21-6
10-2, 11-5
17-7
8-05
4-91
10-3
9-02, 12-0
5-71, 8-93
4-58, 5-45
16-0
5-08
13-0
15-6
13-6
6-89
2-03, 3-58, 6-59,
12-0
12-2, 32-8
10-6, 23-0
7-81, 9-52, 10-7,
11-2, 13-8, 14-6,
17-6, 18-1,
28-1,32-1,34-4
5-29
4-66
2-41
Mean
concen-
tration
5-21
21-2
8-23
14-9
9-87
14-7
Coefficient
of
variation
8-72
43-6
11-0
22-D
31 -3
53.9
10-2 . 46-2
5-82 . 54-3
10-5 . 52-7
12-3 3 26-5
6-05
19-7
12-9
63-
45-5
27-1
31-5 . 9-46
4-12 . 29-8
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No significant difference in the concentration of 65Zn can be associated with
the condition of the prostate. The results for the entire 44 patients studied are
assembled in Table III, grouped according to the status of the gland. For the
four patients with normal prostates, a mean 65Zn concentration of 5*85 ± 2.66*
X 10-3 per cent dose/g. was found; the corresponding average for the five
patients having prostatic malignancy is 7-17 ± 3-63 x 10-3 per cent dose/g.
These levels are lower, but not significantly, than those for the 35 patients having
benign hyperplasia of the gland (average 10-78 ± 6-41 x 10-3 per cent dose/g.).
Since a valid statistical difference is not demonstrable, these 44 patients are
considered a homogenous population having a mean 65Zn concentration of 9-92
+ 6-15 x 10-3 per cent dose/g.
These marked differences in 65Zn concentrations within the prostate are
encountered also on the histological level as demonstrated by radioautography
(Fig. 7-18). While the follicles have a great affinity for the radioisotope, they
exhibit vast differences in this respect. Our preparations indicate that the fol-
licular deposition of 65Zn is spotty. The glandular units frequently involved in
localizing the radioisotope are the smaller ones. Although follicular uptake
varies, both apocrine- and holocrine-like units actively accumulate the radio-
metal. The sequestered cellular material within the holocrine type acini is
strongly labeled. Grains are frequently located over the lumens and ducts,
although never as many as over the border epithelium of the acini. For active
follicles, 65Zn is restricted to the border epithelial cells, principally the cytoplasm.
No significant amounts of activity are present in adjacent muscle and connective
tissues.
The attempts to perform in vivo surveys proved unsatisfactory. While the
detectors indicated higher than background levels when inserted into the rectum,
the counting pattern did not correspond to the anatomical location of the gland.
DISCUSSION
Little is available in the literature regarding the fate of this radioisotope,
particularly its behaviour in man. Adequate studies ofthe fraction ofthe tagged
zinc concentrated in various organs by an appreciable number of human subjects
are yet to be reported. It is consequently difficult to relate our findings with those
published by others.
65Zn as a tracer.-A question meriting evaluation is whether the 65Zn doses
employed by us, as well as those given by others in conducting human and animal
studies, are physiological. The relationship ofthe specific activity ofadministered
65Zn to organ localization requires clarification. This consideration may have
a strong bearing on the discrepancies found between the distribution of radiozinc
and that of stable zinc. For laboratory animals, whose body weights and total
zinc contents are much smaller than those of man, it may well be that the amount
of carrier given has influenced the observed behaviour of 65Zn. Since figures for
specific activity are frequently omitted, the importance of carrier cannot be
assessed for many reports (Tables V and VI).
The 65Zn furnished us has a specific activity ranging between 83-6 and 93-5
nic/g., so that about one-half to one milligram of zinc was contained in each dose.
These amounts of stable zince are small compared to the total body content of
* Standard deviation.DISTRIBUTION OF 65Zn IN MAN
man, approximately 2 grams (Widdowson, McCance and Spray, 1951). The
ingestion of milligram quantities of carrier zinc, corresponding to about one-
tenth of the daily intake of the element (McCance and Widdowson, 1942), may
be consequential. The simultaneous measurements of stable and radioactive
zinc concentrations, as recommended by Vallee (1959), may not prove as valuable
as anticipated unless higher specific activity or even carrier-free 65Zn is employed.
Organ concentration of zinc and 65Zn.-It is interesting to compare the stable
zinc levels found in the various organs of man with the accumulation of 65Zn in
these organs of man, dog, rat and mouse. The available concentration data for
both zinc nuclides have been collected in Table V. The entries have been arbi-
trarily expressed relative to the concentration in the liver to facilitate comparison
and to permit inclusion of more of the published findings. Assuming the body
contains 2-5 grams of the metal, the percentage of the total body zinc in a gram
of each organ has been computed (Table V, column 2), a parameter somewhat
analogous to the expression for concentration of the 65Zn (per cent dose/g.).
The agreement between stable zinc and 65Zn organ to liver concentration ratios
for lung and spleen is good both for man and the laboratory animals; however,
divergent values are encountered for prostate, pancreas and skeletal muscle.
The stable zinc level of the prostate is nearly three times greater than that of the
pancreas and about twice that of the liver. With respect to 65Zn, however,
localization by the prostate is similar to that of the pancreas and about half as
nuch as by the liver. These results are in sharp contrast to the marked affinity
for 65Zn by the dorsolateral prostate of the rat, which takes up almost 11 times
as much as the liver (Gunn et al., 1955). While for man, stable zinc and radiozinc
concentrations in the pancreas are lower than the corresponding liver values,
higher 65Zn ratios of pancreas to liver are reported for the experimental animals.
Thus, it would seem that 65Zn concentrations in the prostate and pancreas of
animals are not indicative of the corresponding behaviour of stable zinc in these
organs of man.
Total zinc and 65Zn in organs.-A knowledge of the total stable zinc content
of various organs as well as the corresponding values for 65Zn would be of signifi-
cance. Making the assumption that the stable metal and radiometal are
distributed uniformlythroughout the organ, an estimate ofthe respective amounts
present can be obtained from their concentrations and the weights of the organs
(Table VI). The validity of this assumption is open to question, particularly in
view of the great variation in 65Zn concentration found within the prostate
(Table IV). This approach has the overriding merit, however, of providing a
basis for a crude analysis of 65Zn kinetics.
Considering the errors made in assuming homogeneous organ distribution of
65Zn and in employing average organ weights, the agreement is surprisingly
good between both forms of zinc for most organs, including the prostate and
pancreas (Table VI). Organ uptake of 65Zn, unlike concentration measurements,
could be thus expected to reflect the handling of stable zinc. The liver, however,
is a notable exception, since it takes up a much higher fraction of the 65Zn dose
than its relative content of the stable metal.
The various organs of man and laboratory animals exhibit differences in
their uptake of 65Zn. While as much as 65 per cent of the 65Zn dose is picked
up by the liver in man, hardly one per cent localizes within the prostate gland,
the lowest of the organs studied. Muscle, because of its huge mass, has the
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TABLE V.-Stable Zinc and 65Zn Concentrations in Man, Dog, Mouse and Rat
Stable zinc
Man
Organ
Liver
Prostate
Skeletal muscle.
Pancreas
Spleen
Lung
Remarks
Reference
Conc.
(y/g. wet*)
101 -13- 9
220 -16- 5
30t
80- 3-10- 4
36-4-9-36
34- 1-7 - 26
Organ cone. x 100
Total body zinct
4-04-0-556 x 10-3
8-80-0 0660
1-20
3-21-0-416
1 460-0374
1-36-0-290
Organ
Liver
1-00-1-00
2- 18-1- 19
0-30
0-794-0-748
0-362-0 672
0-337-0-521
* Wet weights used throught table.
t 2- 5 g. total body zinc assumed.
I Vallee (1959).
Calculated from data of Tipton (1960).
Oirgan
Liver
Prostate
Skeletal muscle
Pancreas
Spleen
Lung
65Zn dose .
Remarks
References_
Conc.
(% dose/g.)
49-4-2-70 x 10-3
31-5-1-50
4-40-0-220
23-0-0-330
12-5-2-07
3-78-0-810
Radioactive zinc (65Zn)
Man
Organ Cone.
Liver (0% dose/g.)
1-00-1-00 40-5 x 10-3
0-638-0 557 28 0-2 34
0-089-0-082 3-57
0-467-0-122 18-2
0-253-0-766 7-15
0-077-0-300
500-100 Pc;
s.a.¶: 83-6-93-5 mc/g.
Range observed for prostates (44
cases) over 196 days; other
organs (14 cases) over 174 days.
¶[ Specific activity.
Montefiore Hospital.
Organ
Liver
1 00
0-690-0-058
0-088
0-450
0- 176
50-100 ,uc;
s.a.: 50-100 mIc/g.
Range observed for pros-
tates (11 cases) over
4 days; other organs,
1 case at 8 days.
Daniel et al. (1956).
Organ
Liver
Prostate
Skeletal muscle .
Pancreas
Spleen
Lung
'aZn dose .
References
Cone.
(% dose/g.)
8 170
hr. hr.
34x10-2 2- 0xI
0-6 1-8
28 6-8
10 3-8
3-4 2-7
Activity (,uc) not stated;
6 52-8-15 ,).
Sheline et al. (1943).
Radioactive zinc (66Zn)
Dog
-k -
Organ Cone. Organ
1,iver (% dose/g.) Liver
,-- - 5
8 170} 8
hr. hr. hr. hr.
10-2 1-00 1-00 14-8 x10-2 1 -00
0-02 0-72
0-82 2-72
0-229 1-52
0-10 1*1(
Mouse
r -- Cone. Organ
(0% dose/g.) Liver
.
2 170 2 170
hr. hr. hr. lhr.
25 4-7 1-00 1-00
1-4 1-2 0-06 0-26-
15-5 1-0O 43 4-9 1-72 1-04
3-1 0-21 12-5 2-5 0-50 0-53
8-0 2-0 0-32 0-43.
100 tw ; s.a. not Activity (,c) not stated;.
stated. 0-33-1 -6 y.
MIeselhan et al.
(1959).
Sheline et al. (1943).
Organ
Liver
1 00
0-21
Activity (yuc)
not stated;
270-380 y.
6 cases, be-
tween 9-23.
days.
Ross et al.
(1958).
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TABLE V contd.
Radioactive zinc (65Zn)
Rnt
Conc. Organ Conc. Organ Organ
(0% dose/g.) Liver (% dose/g.) Liver Liver
4 hr. 92 hr. 4 hr. 92 hr. 3 hr. 10 d. 3 hr. 10 d. 24 hr. 48 hr.
Liver 1-77 0 75 1-00 1-00 3-91 0-34 1 00 1-00 1.00 1-00
Prostate - - - 8-25§ 10 7§
0501 0-53
Skeletal muscle 007 0-19 0 04 0u25 0-14 0-14 0 04 0- 41 1- 85 1- 00
Pancreas 3-11 055 1 76 073 4- 84 0 28 1- 24 0 83
Spleen 0-62 044 035 059 1- 88 0- 21 0-48 0-62
Lung - 0 92 0-19 0 24 0 56
65Zn dose . 75-200 juc ; 5 Iuc; 0-4 mc/kg.;
s.a.: 370-520 inc/g. s.a. not stated. s.a.: 120-164
mclg.
Remarks . § Dorsolateral
prostate.
Ventral pro-
state.'
Referenices SIclsa'ac (195.5). Bnllou (1959). Gunn et al.
(1955).
maximum uptake. It is interesting to note that both the spleen (about 6 per
cent) and the lung (about 5 per cent) take up more than the pancreas (2.7 per
cent), an organ once believed to be very much concerned with zinc metabolism.
Our figures are in fair accord with the scanty data available pertaining to man
(Daniel et al., 1956; Prout et al., 1959; Ross et al., 1958) and the dog (Sheline
et al., 1943; Meschan et al., 1959), but are higher than the corresponding values
for the mouse (Sheline et al., 1943) and rat (Gilbert and Tavlor, 1956; Ballou,
1959).
The variation of 65Zn uptake in the liver with time is noteworthy (Fig. 19).
The maximum level occurs about the seventh day, declining quite slowly there-
after. As late as 174 days after injection, 3 8 per cent of the dose is still present
in the liver. In comparison to the mouse and dog, the levels and turnover of
65Zn in the liver of man are quite different (Fig. 19). The peaks for the animals
are reached early, before the end ofthe first day. Furthermore, the disappearance
of 65Zn in the mouse and dog is so rapid, that by the end of the first week, only
3*3 per cent of the dose remains in the liver of the mouse and 3-5 per cent in the
same organ of the dog. Gilbert and Taylor (1956) have also observed an early
fall of 65Zn uptake in the liver of the rat, so that only 1 6 per cent of the dose is
retained 35 days after administration of the dose.
As the determinations of permissible levels of 65Zn in man have been hitherto
based on animal studies (National Bureau of Standards, 1959), the values and
the turnover being reported here may have a bearing on these calculations.
Bone is being taken as the critical organ, since the studies in animals conducted
by Sheline et al., (1943) indicate a longer biological half-life of administered 65Zn
in bone than either in liver or in pancreas. As noted earlier, while both of the
latter organs in man accumulate high levels of 65Zn rapidly, the turnover in the
pancreas is faster. Our data indicate that the biological half-life of 65Zn in the658 E. SIEGEL, F. A. GRAIG, M. M. CRYSTAL AND ELSIE P. SIEGEL
liver of man is about 75 days, a gross estimate because of the few points available-
(Fig. 19). Although considerable error is associated with this value, it is certainly
longer than the 23 days found for bone of the dog (Sheline et al., 1943). Further
studies along these lines are needed to establish more precisely the turnover in
human bone and liver in order to reduce the uncertainty in dosage computations.
TABLE VI. Stable Zinc and 65Zn Uptake (per cent dose/organ)
in Man, Dog, Mouse and Rat
Stable zinc
Man
Crgan
Liver
Prostate
Skeletal muselet
Pancreas
Spleen
Lung
Assumed
organ wt.
(g.)
2,000
30
30,00()
100
200
1,000
Organ zinc
(g.)
0C202-0-0278
0-00669-0000050
0 9001
0-00803-0-00104
0001728-0-00187
0-0341-0-00726
Organ zinc x 1(00
Body zinc*
8 (8-1-11
0-264-0-0200
36 0
0-321-0-0416
0-291-0-0748
1-36-0 290
Cal'-ulated from data of Tipton (1960).
Radioactive zinc (65Zr1)
M,-an
Organ
Liver
Prostate
Skeletal muselet
Pancreas
Spleen
Lung
References
Uptake
65-5-3-78
0-945-0-033
92-5-5-81
2-67-0-033
5-86-0-644
4-94-0-972
Organ
Livcrl
1-00--1 00
0-014-0-009
1-41-1-54
0 0X1-0-009
009-0-170
0-076 -0-257
Montefiore Hospital.
Uptake
31
0-840-0-058
85
1-82
1-43
Organ
Liver
1 -00
0-010-0-001
1-05
0-023
0-018
Dainiel ct al. (1956).
Organ
Uptake Liver
35* 6 1-(0
0-69 0-019
Ross et al. (1958).
Radioc -tive zinc (65Zn)
Organ
Liver
Prostate
Skeletal muselet
Pancreas
Spleen
Lung
References
Uptake
8 170
hr. hr.
34 3-5
9-6 36
3-1 0-69
0-93 0-31
0-73 0- 71
Dog
Organ
Liver
8 170
hr. hr.
1-00 1-00
0-28 10-3
0 09 0-20
0-03 0-09
0-02 0-20
Sheline ct al. (1943).
Up-
take
8
hr.
87-3
4- 1
4-4
Organ
Liveri 1
Q *)
hr. h
1-00 25
Vptal
r.
MNiouse
Organ
k-e Liver
170 2 170
hr. hr. hr.
3-3 1-00 1-00
0-05 1-7 0-44 0-07 0-13
0-05 1-3 0-14 0-05 0-04
1-1 0-26 0-04 0-08
Meschan et Sheline et al. (1943).
al. (1959).
* 2-5 g. total body zinc assumed.
t Assuming 41 per cent body weight is muscle.
+ Calculated, based on value in Vallee (1959).
§ 2 ,lc 65Zn, specific activity: 8 curies/g.; all other 65Zn doses indicated in Table V.
Rat
Up- Organ
take Liver
35 35
d. d.
1- 6 1-00
0-1 0-(6
Gilbert and
Taylor
(1956)l.
Reference
Organ
Liver
1*00-1-00
0-033-0-018
4-45-32 - 7
0-040-0-038
0-360-0-067
0-168-0-2(;61
x-DISTRIBUTION OF 65Zn IN MAN 659
65Zn in bone marrow.-The high uptake of 65Zn by leucocytes as compared to
-erythrocytes demonstrated by our radioautographs confirm observations based
-on studies with stable zinc and recently with 65Zn. Thus, it is believed that the
leucocyte probably contains more zinc than any other cell of the body (Vikbladh,
1951); the white cells have as much as 3 per cent of whole blood zinc (Vallee
-and Gibson, 1948). The zinc ratio of leucocyte to erythrocyte is about 20 (Ross
et al., 1958) or 15 (Dennes, Tupper and Wormall, 1961). This latter group has
found also that two hours after incubation of whole blood with a 65Zn-glycine
solution, the leucocyte to erythrocyte ratio for the radioisotope is about 57. Of
mnore direct interest are their experiments in rabbits, indicating that 24 hours
60
ui 50 100-
1^ ~~~~~~~~~~~80
20 N 61 MAN
7 ~~~~~~i40\
Z 40 0 MAN
u20 N I l20
0 2 3 4 5 6 7 8 9
TIME (DAYS)
FIG. 19.-'6Zn liver uptake for man compared to the values reported by Sheline et al. (1943)
for dog and mouse. Each point plotted for the mouse refers to the average of 3-7 animals.
For man and for dog, each point represents the uptake of a single subject. In.set.-The
long-term variation of 6&Zn uptake by the human liver is graphed semi-logarithmically.
after administration of 65Zn, a similarly high ratio (about 30) is found in the bone
marrow.
65Zn in the prostate.-A dominant feature of the findings presented here is the
low and variable total uptake of 65Zn by the human prostate (Table IV). As
.already remarked, hardly one per cent of the administered radioisotope is taken
up by the gland, an approximate value in view of the non-uniform 65Zn con-
*centration within the organ. In any event, 65Zn in the prostate of man does not
.approach the concentration and uptake of 131J by the thyroid, as had been claimed
(Gunn et al., 1955).
The fluctuation of prostatic 65Zn concentration among our patients is con-
siderably greater than that reported by others. While an eight-fold variation
was found in the necropsy specimens from eight male patients, an even greater
ratio of about 15 was encountered in the surgical specimens from 36 patients660 E. SIEGEL, F. A. GRAIG, M. M. CRYSTAL AND ELSIE P. SIEGEIL
(Table III). A factor of only 12 is indicated in the series of 15 patients studied
with 65Zn by Daniel et al. (1956) and an even smaller ratio, about seven, is found
for the 21 cases investigated by Prout et al. (1959). It should be noted that
stable zinc levels are likewise variable, Hoare, Delory and Penner (1956) having
observed an 11-fold range in 19 normal prostates.
Our observation that the variation of 65Zn concentration within the gland
is unrelated to anatomy (Table IV) does not agree with some stable zinc determina-
tions in man or with radiozinc studies in the rat. Thus, Kerr, Kerestechi and
Mayoh (1960) concluded that levels of stable zinc increase toward the apex of
the human prostate. They found great variations in concentration of the metal,
as much as 18-fold, for different portions of the gland. On the other hand,
Mager, McNary and Lionetti (1953), using histochemical methods, could not
detect differences in zinc content between the anterior and posterior lobes of the
human, canine and simian prostates. In the rat, Gunn et al. (1955) found that
the dorsolateral prostate concentrates about 20 times as much 65Zn as the ventral
portion. More recently, they have shown that the lateral tip of the dorsolateral
gland, composed exclusively of apocrine type acini, is concerned with 65Zn up-
take, but is low in fructose ; the dorsal tip, however, comprised of holocrine-
like units, is devoid of 65Zn, but is high in fructose (Gunn and Gould, 1957).
The low uptake of 65Zn by the prostate together with the relatively high levels
of the radioisotope in the liver, bladder and blood (Graig and Siegel, 1960)
account, we believe, for our failure to perform satisfactory measurements of
uptake by the prostate using rectal detectors. This comparatively poor localiza-
tion dims the hope of applying such in vivo counting techniques for diagnosis or
for determining indices of function, unless much higher ratios are encounltered
for pathological states ofthe prostate. Our findings are in accord with the meager
evidence available (Mawson and Fischer, 1952 ; Daniel et al., 1956; Prout et
al., 1959; Kerr et al., 1960) which suggests that the reverse is more probable.
Neither 65Zn concentration nor total uptake by the prostate was founld to
vary with the period elapsing between administration of the radioisotope and
removal of the specimen, a disturbing finding. This is obviously not a firm
conclusion, since it is based on single observations for each patient. The marked
variation in 65Zn concentration, the error made in estimating the weight of the
gland, and the unknown role of carrier already alluded to, are additional factors.
obscuring any temporal relationship, if indeed one exists.
65Zn concentration and prostatic status. We were unable to demonstrate
a correlation between the concentration of the tracer and the state ofthe prostate.
Such a relationship might be expected in view of the stable zinc determinations
indicating depressed concentrations in the presence of malignancy (Mawson and
Fischer, 1952; Hoare et al., 1956; Kerr et al., 1960). While the mean 65Zn1
concentration of the five malignant prostates in our series is higher than the aver-
age for the four normal glands and lower than that of the 35 benign hyperplastic
prostates, the differences are not statistically significant due to the very great
dispersion among the individual values. Among 15 patients investigated, Daniel
et al. (1956) found that the 65Zn concentrations in two of their three malignant
prostates were not appreciably lower. Indeed, the highest 65Zn level in any tissue
studied by them occurred in the untreated prostatic carcinoma of their third
patient. Prout et al. (1959) encountered in only one of 12 malignant prostates a
markedly lower concentration of the tracer than in adjacent normal tissues.DISTRIBUTION OF 65Zn IN MAN
Additional studies involving larger series of patients are still required to establish
whether a relationship does actually exist between concentration of the tracer
by the gland and its pathology.
Age and 65Zn concentration in prostate.-An interesting question is raised as a
result of arranging the 65Zn concentration in the prostate according to the age
of the patient (Table VII). Does the concentration of 65Zn rise with age, attain-
TABLE VII. 65Zn Concentration (per cent dose/g. wet weight x 10-3)
in the Prostates of 44 Patients as a Function of Age
Nuniber of
Decade patients Average Range
30-39 1 4- 46
40-49 1 5.60
50-59 6 6-91 1 87-14 7
60-69 7 10-82 2-44-21*2
70 79 22 11 71 3 26 31-5
80-89 7 9.40 5-82-13-7
ing miaximnum values in the seventies, to decline thereafter? The variation in
the concentration data precludes a definitive response, but further inquiry seems
warranted. It is noteworthy that this trend of increasing concentration with age
is present also in the data of Prout et al. (1959) for their nine patients with benign
hyperplasia. Perhaps this rise in 65Zn with age is related to the corresponding
increase in weight of the prostate and its decrease sometime during the eighth
decade (Simnmonds, 1918). In this connection, mention should be made of the
finding of Fischer et al. (1955) that the stable zinc concentration of the dorso-
lateral prostate of the rat increases with age, reaching a maximum at about 160
(lays. Gunn et al. (1955) also found that the prostates ofrats six months and older
picked up the largest amounts of 65Zn.
Cellular and intracellular 65Zn in the prostate. The wide fluctuation in 65Zn
content in the prostate gland, determined grossly by sample counting, is also
found on a histological level by radioautography, which demonstrates that the
follicles differ in their affinity for 65Zn. Histochemical confirmation is provided
by;the studies performed with dithizone staining of the prostates of developing
rats (Fischer et al., 1955). As the rats become able to breed (about 50 days),
a few areas within isolated acini become stainable. Several days thereafter,
scattered acini are seen in which all the cells react positively. Spotty activity
of follicles has been encountered in the study of other glands, an outstanding
example being the thyroid gland with respect to its variable localization of 131I.
Some of the other findings from our radioautographs are also in good agree-
ment with the literature. The localization of 65Zn by the border epithelium is in
accord with the radioautograph published by Daniel et al. (1956) for human
prostate and with those presented by Wetterdal (1958) and Millar, Vincenlt and
Mawson (1961) for the dorsolateral prostate of the rat. Using the dithizone
stain, Mager et al. (1953) studied the prostates of the dog, man, monkey and rabbit,
reporting that the apical portions of the secretory cells were most intensely
stained. They found that the associated connective and muscle tissues did not
contain zinc. Employing a dithizone complex-forming solution to enhance
specificity for zinc, this group showed, also, that the nuclei were non-staining.
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Fleischhauer (1957) has also observed stainable zinc in the apical border of pro-
static cells in the rat, but the distal portions of the epithelium concentrated the
metal only slightly; the periphery of the nucleus was occasionally positive for
zinc. Gunn and Gould (1956) published a photomicrograph which demonstrated
positive staining of the acini at the luminal border in the lateral prostate of the
rat. Rixon and Whitfield (1959) confirmed this high concentration of zinc in
lateral portions of the dorsolateral prostate of the rat, finding three regions witl
positive staining: apical cytoplasm, nucleoli and sub-epithelial stroma.
In spite of the evidence just cited and confirmed by our radioautographs. the
observation that the nuclei of the apical epithelium contain little or no 65Zn is
unexpected, in view ofthe distribution ofstable zinc in animal tumours and livers.
Heath (1949) and Heath and Liquier-Milward (1950) have reported that zinc is.
associated with nucleoprotein from tumour tissues. Zinc has been found also
in the nuclear fractions ofnornmal rat livers (Thiers and Vallee, 1957) and of mouse-
mammary tumours and livers (Bartholomew, Tupper and Wormall, 1959). It
should be remarked, however, that Rosenfeld and Tobias (1951) were unable to
detect nucleoprotein-bound zinc in their studies.
The radioautographs inldicate that both holocrine and apocrine types of
follicles can actively pick up 65Zn. As already noted, Gunn and Gould (1957)
have shown that the lateral tips of the dorsolateral prostate, which are concerned
with the localization of the radioisotope and devoid of fructose, are comprised
exclusively of apocrine type acini. Conversely, the dorsal tips, which have a
higher fructose content and reduced 65Zn levels, have only holocrine units. The
situation in man is, apparently, unlike that which prevails in the rat.
SUMMARY
The distribution of 65Zn was studied in the organs of 14 patients at autopsy,
occurring between 1 and 174 days following administration of 100 ,uc. The
greatest concentration of the radioisotope is reached within a few days in the liver
(about 0 050 per cent dose/g. wet weight), which localizes about 2-8 times more
than the pancreas and as much as 10-30 times more than muscle. 65Zn leaves
the liver slowly, 0-013 per cent dose/g. still being present 81 days after infusion.
A more rapid turnover of the administered radioisotope occurs in the pancreas.
In this organ, the maximum concentration (about 0-023 per cent dose/g.) is
attained by the second day; within a week, the level of the tagged metal has
fallen by two-thirds, and bv 81 days, hardly a tenth remains. The maximum
concentration of 65Zn in the spleen (0-013 per cent dose/g.) is about half that ofthe
pancreas. For the spleen, as well as for those organs having even lower levels of
the radioisotope (seminal vesicles, lung, bladder and muscle), no temporal rela-
tionship could be discerned.
The prostatic localization of 65Zn was studied by assaying autopsy specimen
from 8 ofthese patients and surgical specimens from 36 others undergoing surgery.
For the entire series of 44 patients having normal, hyperplastic, or malignant
prostates, the mean 65Zn concentration is 0-00992 ± 0-00615 per cent dose/g.,
ranging between 0-0315 and 0-00150; these 65Zn values are second only to those
of the liver. No correlation could be demonstrated between the concentration of
the radiometal and the condition ofthe prostate. By assaying samples ofdifferent
lobes from the hyperplastic glands of 15 patients, marked variation in 65ZnDISTRIBUTION OF 65Zn IN MAN 663
concentrations is encountered within the organ unrelated to the anatomical sub-
divisions. Radioautographs of prostatic sections reveal that the deposition of
the radioisotope, which is largely confined to the border epithelial cells, is not
uniform. The smaller follicles accumulate the radioisotope predominantly,
with both apocrine and holocrine type acini participating. Lesser amounts of
the tagged metal are found in the lumens and ducts. f5Zn is concentrated
principally by the cytoplasm of these border epithelial cells, insignificant amounts
being taken up by the nuclei and by the associated connective and muscle tissues.
Radioautographs, prepared from bone marrow aspirates obtained about one
week after 65Zn infusion, show that megakaryocytes and all early forms of the
hematopoietic series are very heavily labeled. Mature leucocytes take up some
65Zn, but comparatively little of the nuclide is present in the erythrocytes.
The distribution pattern of the radioisotope is discussed in relation to stable
zinc determinations in man. Our 65Zn data are compared also to those reported
for experimental animals. Assuming uniform concentration throughout the
organ, estimates are made oftotal organ uptake of65Zn. The maximum accumula-
tion of the administered tracer occurs in skeletal muscle and in liver, while pan-
creas and prostate have by far the lowest uptake. The effect of some factors on
prostatic levels of 65Zn is considered. The intracellular deposition of 65Zn by
the prostate of man is compared to the histochemical studies of stable zinc in
man and experimental animals.
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